Dehydroepiandrosterone supplementation confers benefits for quality of life (QoL) but not for disease activity relative to placebo in premenopausal women with rheumatoid arthritis (RA), a study has found.
A growing waistline increases the risk of incident low physical function in the following year among adults with knee osteoarthritis (OA), suggests a recent study. Maintaining waist circumference (WC) may prevent the development of low physical function.
Romilkimab, a novel bispecific immunoglobulin-G4 antibody that binds and neutralizes interleukin (IL)-4/IL-13, shows promise in the treatment of diffuse cutaneous systemic sclerosis, producing significant reduction in skin fibrosis, according to the results of a phase II trial.
Obesity is tied to adverse outcomes in ankylosing spondylitis, including inflammation, disease activity, physical mobility, radiographic damage, health index, liver function, and cardiovascular risk factors, a study suggests.
The novel Wnt pathway modulator lorecivivint does not appear to be effective for treating pain and inhibiting structural progression in moderate-to-severe knee osteoarthritis (OA), according to the results of a phase IIa trial.
Ritlecitinib, an oral JAK3/TEC inhibitor, appears to be well tolerated and produce significant improvements disease activity in patients with rheumatoid arthritis, according to the results of a phase II study.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.